In Vitro Chemo-Sensitivity Assay Guided Chemotherapy is Associated with Prolonged Overall Survival in Cancer Patients

• Authors: Andrej Udelnow , Manfred Schönfelder , Peter Würl , Zuhir Halloul , Frank Meyer , Hans Lippert , Paweł Mroczkowski
• Languages of publication: EN

Abstracts

EN

The overall survival (OS) of patients suffering From various tumour entities was correlated with the results of in vitro-chemosensitivity assay (CSA) of the in vivo applied drugs.Material and methods. Tumour specimen (n=611) were dissected in 514 patients and incubated for primary tumour cell culture. The histocytological regression assay was performed 5 days after adding chemotherapeutic substances to the cell cultures. n=329 patients undergoing chemotherapy were included in the in vitro/in vivo associations. OS was assessed and in vitro response groups compared using survival analysis. Furthermore Cox-regression analysis was performed on OS including CSA, age, TNM classification and treatment course.Results. The growth rate of the primary was 73-96% depending on tumour entity. The in-vitro response rate varied with histology and drugs (e.g. 8-18% for methotrexate and 33-83% for epirubicine). OS was significantly prolonged for patients treated with in vitro effective drugs compared to empiric therapy (log-rank-test, p=0.0435). Cox-regression revealed that application of in vitro effective drugs, residual tumour and postoperative radiotherapy determined the death risk independently.Conclusions. When patients were treated with drugs effective in our CSA, OS was significantly prolonged compared to empiric therapy. CSA guided chemotherapy should be compared to empiric treatment by a prospective randomized trial.

Keywords

EN

chemo-sensivity in vitro; survival prediction; chemotherapy; drug sensivity; cancer

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2013
• Volume: 85
• Issue: 6
• Pages: 340-347

Dates

published

1 - 06 - 2013

online

05 - 07 - 2013

Contributors

author

Andrej Udelnow

• Department of General, Visceral and Vascular Surgery, University Hospital in Magdeburg, Abteilung Chirurgie Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Leipziger Straße 44 39120 Magdeburg Niemcy, Germany

author

Manfred Schönfelder

• Department of Visceral, Vascular, Thoracic and Transplantation Surgery, University Hospital in Leipzig, Germany

author

Peter Würl

• Department of Visceral and Thoracic Surgery, Diakonie Hospital in Halle (Saale), Germany

author

Zuhir Halloul

• Department of General, Visceral and Vascular Surgery, University Hospital in Magdeburg, Germany

author

Frank Meyer

• Department of General, Visceral and Vascular Surgery, University Hospital in Magdeburg, Germany

author

Hans Lippert

• Department of General, Visceral and Vascular Surgery, University Hospital in Magdeburg, Germany

author

Paweł Mroczkowski

• Department of General, Visceral and Vascular Surgery, University Hospital in Magdeburg, Germany

References

• 1. Butler D: Translational research: crossing the valley of death. Nature 2008; 453(7197): 840-42.[WoS]
• 2. Adams DJ: The valley of death in anticancer drug development: a reassessment. Trends PharmacolSci 2012; 33(4): 173-80.[Crossref]
• 3. Weisenthal LM, Shoemaker RH, Marsden JA et al.: In vitro chemosensitivity assay based on the concept of total tumor cell kill. 1984.[PubMed]
• 4. Neoptolemos JP, Moore MJ, Cox TF et al.: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the espac-3 periampullary cancer randomized trial. JAMA 2012; 308(2): 147-56.[WoS]
• 5. Rothenberg ML, Oza AM, Bigelow RH et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase iii trial. J Clin Oncol 2003; 21(11): 2059-69.[PubMed][Crossref]
• 6. Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. NEngl J Med 2000; 342(25): 1878-86.
• 7. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342(25): 1887-92.
• 8. Sackett DL: Evidence-based medicine and treatment choices. Lancet 1997; 349(9051): 570; author reply 572-570; author reply 573.
• 9. Rubin DB, Rosenbaum PR: Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. TheAmerican Statistician 1985; 39(1): 33-38.
• 10. Oktay MH, Hui P: Molecular pathology as the driving force for personalized oncology. Expert RevMol Diagn 2012; 12(8): 811-13.
• 11. Schoenfelder M: Das onkobiogramm - ein wegweiser fuer die chemotherapie. Zbl Chir 1974; 99: 1198-1208.
• 12. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 1974; 197: 461-63.
• 13. Koechli OR, Avner BP, Sevin BU et al.: Averette. Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: a report on the first results. J SurgOncol 1993; 54(2): 119-25.
• 14. Bertelsen CA, Sondak VK, Mann BD et al.: Chemosensitivity testing of human solid tumors. a review of 1582 assay with 258 clinical correlations. Cancer 1984; 53: 1240-45.
• 15. Andreotti PE, Cree IA, Kurbacher CM et al.: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminiscence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
• 16. Crohns C, Konecny G, Blokh E et al.: Is there a role for pretherapeutic chemosensibility testing in breast cancer? Gynaekologe 1999; 32: 705-09.
• 17. Taylor CG, Sargent JM, Elgie AW et al.: Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynecol Oncol 2001; 22(4): 278-82.
• 18. Singh B, Li R, Xu L et al.: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002; 24(5): 437-42.[Crossref]
• 19. Samson DJ, Seidenfeld J, Ziegler K, AronsonN: Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004; 22(17): 3618-30.[PubMed][Crossref]
• 20. Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. JClin Oncol 1999; 17(5): 1625-31.
• 21. R Development Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2010; ISBN 3-900051-07-0.
• 22. Terry Therneau and original Splus->R port by Thomas Lumley. survival: Survival analysis, including penalised likelihood., 2010; R package version 2.36-2.
• 23. Ho DE, Imai K, King G, Stuart EA: Matchit: Nonparametric preprocessing for parametric causal inference. Journal of Statistical Software 2011; 42(8): 1-28.
• 24. Weller M: Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998; 292(3): 435-45.
• 25. Campling BG, Pym J, Baker HM et al.: Chemosensitivity testing of small cell lung cancer using the mtt assay. Br J Cancer 1991; 63(1): 75-83.[Crossref]

Identifiers

DOI

10.2478/pjs-2013-0051